These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 16462689)

  • 21. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
    Entsuah AR; Huang H; Thase ME
    J Clin Psychiatry; 2001 Nov; 62(11):869-77. PubMed ID: 11775046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
    J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
    Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
    CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T3 augmentation of SSRI resistant depression.
    Abraham G; Milev R; Stuart Lawson J
    J Affect Disord; 2006 Apr; 91(2-3):211-5. PubMed ID: 16483669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment.
    Bauer M; Demyttenaere K; El-Khalili N; Thase ME; Papakostas GI; Szamosi J; Earley WR; Eriksson H
    Int Clin Psychopharmacol; 2014 Jan; 29(1):16-25. PubMed ID: 24108148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control.
    Kasper S; Corruble E; Hale A; Lemoine P; Montgomery SA; Quera-Salva MA
    Int Clin Psychopharmacol; 2013 Jan; 28(1):12-9. PubMed ID: 23023074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Remission in major depression with two antidepressant mechanisms: results from a naturalistic study.
    Montes JM; Ferrando L; Saiz-Ruiz J
    J Affect Disord; 2004 Apr; 79(1-3):229-34. PubMed ID: 15023499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
    Ball S; Dellva MA; D'Souza DN; Marangell LB; Russell JM; Goldberger C
    J Affect Disord; 2014; 167():215-23. PubMed ID: 24995890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment.
    Milak MS; Parsey RV; Lee L; Oquendo MA; Olvet DM; Eipper F; Malone K; Mann JJ
    Psychiatry Res; 2009 Jul; 173(1):63-70. PubMed ID: 19446443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study.
    McIntyre A; Gendron A; McIntyre A
    Depress Anxiety; 2007; 24(7):487-94. PubMed ID: 17177199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.
    Fava M; Thase ME; DeBattista C
    J Clin Psychiatry; 2005 Jan; 66(1):85-93. PubMed ID: 15669893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder.
    Herrera-Guzmán I; Gudayol-Ferré E; Herrera-Guzmán D; Guàrdia-Olmos J; Hinojosa-Calvo E; Herrera-Abarca JE
    J Psychiatr Res; 2009 Jun; 43(9):855-63. PubMed ID: 19128810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
    Goldstein DJ; Mallinckrodt C; Lu Y; Demitrack MA
    J Clin Psychiatry; 2002 Mar; 63(3):225-31. PubMed ID: 11926722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors associated with response in depressed elderly outpatients treated with escitalopram in a naturalistic setting in Germany.
    Möller HJ; Schnitker J; Flürenbrock W
    Pharmacopsychiatry; 2010 Aug; 43(6):210-5. PubMed ID: 20589597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attributes of response in depressed patients switched to treatment with duloxetine.
    Sagman D; McIntosh D; Lee MS; Li H; Ruschel S; Hussain N; Granger RE; Lee AC; Raskin J
    Int J Clin Pract; 2011 Jan; 65(1):73-81. PubMed ID: 21078010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Use of antidepressant drugs in schizophrenic patients with depression].
    Micallef J; Fakra E; Blin O
    Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
    Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
    J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Response and remission in depressive patients with anxiety symptoms treated with venlafaxine extended release in primary care].
    Roca Benassar M; Baca Baldomero E
    Actas Esp Psiquiatr; 2006; 34(3):162-8. PubMed ID: 16736389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational Cohort Study.
    Castellano S; Ventimiglia A; Salomone S; Ventimiglia A; De Vivo S; Signorelli MS; Bellelli E; Santagati M; Cantarella RA; Fazio E; Aguglia E; Drago F; Di Nuovo S; Caraci F
    CNS Neurol Disord Drug Targets; 2016; 15(10):1290-1298. PubMed ID: 27712575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.